MRSA Drugs Global Strategic Research Report 2024: Market to globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
The global precocious puberty treatment market is anticipated to attain an impressive valuation of US$ 1,716.43 million in 2023 and is projected to reach US$ 3,650.66 million by 2033, trailing a CAGR of 7.8% during the forecast period. The focus of key industry players on getting product approval from regulatory aut.
Antibody-drug conjugates the next pillar of cancer therapeutics healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
The combination of pembrolizumab plus axitinib continued to improve overall survival, progression-free survival, and overall response rate over sunitinib monotherapy in patients with treatment-naïve clear cell renal cell carcinoma.
CHICAGO — Trastuzumab deruxtecan showed clinically meaningful activity against several types of HER2-expressing solid tumors, according to interim results of the DESTINY-PanTumor02 study presented at ASCO Annual Meeting.The HER2-directed antibody-drug conjugate, also known as T-DXd (Enhertu; AstraZeneca, Daiichi Sankyo), demonstrated the highest objective response rates and most durable